Clinical trials: Never Smokers
Lung Cancer
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00754923
- Testing
- sorafenib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lung Cancer
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00445848
- Testing
- bevacizumab, erlotinib hydrochloride
- Where
- 153 sites in United States
- Volunteers
- 89 people
- Sponsor
- SWOG Cancer Research Network
Smokers, Never Smokers
Prefatory Study to Explore Changes in Nasal Mucociliary Clearance and to Standardize Nasal Scraping Procedure
This study intends to evaluate the nasal mucociliary clearance (NMC) by determining the value obtained for saccharin transit time (STT) test over the course of 12 hours following a single cigarette use in adult smokers, to…
- Trial name
- NCT03086707
- Testing
- Cigarette
- Where
- 2 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Lung Cancer
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01344824
- Testing
- bevacizumab, carboplatin, erlotinib hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non Small Cell Lung Cancer
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants.
- Trial name
- NCT01017874
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 236 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
The purpose of this study is to test the drug Bortezomib to see how well it works. The investigators want to find out what effects, good or bad, it has on patients with a limited smoking history or who have a specific mutation…
- Trial name
- NCT01833143
- Testing
- Bortezomib, Acyclovir
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer
Sunitinib in Never-Smokers With Lung Adenocarcinoma
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01829217
- Testing
- Sunitinib
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Dana-Farber Cancer Institute
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
This randomized phase II trial studies how well erlotinib hydrochloride with or without carboplatin and paclitaxel works in treating patients with stage III-IV non-small cell lung cancer.
- Conditions
- Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Malignant Pericardial Effusion, Malignant Pleural Effusion
- Trial name
- NCT00126581
- Testing
- Carboplatin, Erlotinib, Erlotinib Hydrochloride
- Where
- 96 sites in United States
- Volunteers
- 188 people
- Sponsor
- National Cancer Institute (NCI)
COPD
Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
Chronic obstructive pulmonary disease (COPD) is a common inflammatory disease of the airway affecting approximately 10% of individuals aged 40 years or more with a smoking history.
- Trial name
- NCT01780298
- Where
- United Kingdom
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Non-small Cell Lung Cancer
Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers
The purpose of this study is to compare the efficacy and safety of chemotherapy followed sequentially by gefitinib versus chemotherapy alone in the first line treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT00409006
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 7 sites in China, South Korea and 1 more
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company